ArticleOncogene2018
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
A Esteve-Arenys et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
this paperpooled itcites it